Celebrating its 5th edition, the B2B Uro-Oncology: GU Cancers Triad meeting returns to the  43rd  Annual Congress  in Istanbul, Türkiye, on Friday, October 13, 2023, for a full in-person programme, showcasing the latest innovations in uro-oncology. View the programme agenda here.

About the B2B Uro-Oncology: GU Cancers Triad  

The rapidly evolving treatment landscape for bladder, kidney, and prostate cancers poses a challenge for urologists, medical oncologists, and radiation oncologists alike. In managing these GU cancers, physicians need to keep up with new data on therapeutic options, provide individualized care through a multidisciplinary approach, and use optimal treatment sequence or combinations while effectively managing side effects. 

Aiming to support the educational needs of urologists and allied healthcare practitioners, the B2B Uro-Oncology: GU Cancers Triad meeting will feature multidisciplinary, scientific, and educational sessions highlighting cutting-edge content in management of the most prevalent GU malignancies: prostate, bladder, and kidney cancers. Through state-of-the-art presentations, timely debates, and interactive panel discussions, world-renowned experts in GU oncology will: 

  • Examine advances in the use of novel biomarkers and artificial intelligence to guide the diagnosis and treatment of GU cancers 
  • Discuss recent developments in local and systemic therapy approaches in GU oncology and their implications for clinical practice 
  • Evaluate new diagnostic and surgical technologies changing the landscape of GU cancers management 
  • Summarize emerging data of key ongoing clinical trials in the uro-oncology space 
  • Provide an overview of the five practice changes shaping the GU cancers practice in coming years 

Meet this year's expert faculty!

Learning Objectives

At the end of this programme, participants will be able to:

  • Evaluate the benefits and risks of various treatment options across the treatment continuum in bladder cancer, renal cell carcinoma, and prostate cancer. 
  • Analyze novel agents and treatment approaches for the evolving management of GU cancers based on emerging clinical data. 
  • Discuss strategies to identify and manage adverse events related to systemic treatment, including immunotherapy. 
  • Evaluate the role of imaging or genetic markers in guiding treatment decision-making. 
  • Discuss the importance of personalized medicine, based on costs and patient preference, while minimizing toxicity and maximizing efficacy. 


The 5th B2B Uro-Oncology: GU Cancers meeting will be transmitted live onSIU@U  and webcasts will also be made available on-demand. Keep the conversation going by sharing your thoughts and questions with colleagues on social media using #B2BGUCancersTriad 


Available now, the full Programme Agenda for review. 


Follow Us